Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid CancersLori J. Wirth, Maria E. Cabanillas, Eric J. Sherman et al.|New England Journal of Medicine|2020Cited by 766
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S. Weber, Tal Zaks, Montaser Shaheen et al.|The Lancet|2024Cited by 729
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven CancersVivek Subbiah, Erica Evans, Justin F. Gainor et al.|Cancer Discovery|2018Cited by 392
PD-1 Blockade in Anaplastic Thyroid CarcinomaJaume Capdevila, Matthew H. Taylor, Lori J. Wirth et al.|Journal of Clinical Oncology|2020Cited by 349
Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.Robert Hans Ingemar Andtbacka, Kenneth F. Grossmann, Merrick I. Ross et al.|Journal of Clinical Oncology|2017Cited by 55